Chee Conley
SEC insider (Form 3/4/5 filer). CIK 0001883804. President & CEO at Syros Pharmaceuticals, Inc. (SYRS). 5 reported Form 4/5 transactions since Sep 2024; latest on Nov 18, 2024. Located in CAMBRIDGE, MA.
Companies Chee Conley has filed insider reports for
- Syros Pharmaceuticals, Inc. (SYRS): Director, Officer, President & CEO
Chee Conley
CIK: 0001883804
Transaction Breakdown
Open Market Buys (P)2 (40.0%)
High conviction signal
Open Market Sales (S)1 (20.0%)
Position reduction
Option Exercises (M)1 (20.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)1 (20.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SYRS
Syros Pharmaceuticals, Inc.
DirectorOfficer
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Nov 18, 2024SYRS
Syros Pharmaceuticals, Inc.
SaleDirect134.8K shares at avg. $0.20$27K - Oct 31, 2024SYRS
Syros Pharmaceuticals, Inc.
ExerciseDirect17K shares- - Oct 31, 2024SYRS
Syros Pharmaceuticals, Inc.
Tax PaymentDirect8.7K shares at avg. $2.09$18K - Sep 11, 2024SYRS
Syros Pharmaceuticals, Inc.
PurchaseDirect50K shares at avg. $1.71$85K - Sep 10, 2024SYRS
Syros Pharmaceuticals, Inc.
PurchaseDirect50K shares at avg. $1.51$75K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Nov 18, 2024 | SYRS Syros Pharmaceuticals, Inc. | Sale | 134,797 | $0.20 | $26,932 | Direct |
| Oct 31, 2024 | SYRS Syros Pharmaceuticals, Inc. | Exercise | 17,000 | - | $0 | Direct |
| Oct 31, 2024 | SYRS Syros Pharmaceuticals, Inc. | Tax Payment | 8,707 | $2.09 | $18,198 | Direct |
| Sep 11, 2024 | SYRS Syros Pharmaceuticals, Inc. | Purchase | 50,000 | $1.71 | $85,420 | Direct |
| Sep 10, 2024 | SYRS Syros Pharmaceuticals, Inc. | Purchase | 50,000 | $1.51 | $75,260 | Direct |
1-5 of 5 transactions